Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Emory University, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Front Horm Res. 2021;54:25-35. doi: 10.1159/000515111. Epub 2021 Apr 30.
Growth hormone deficiency (GHD) is common in childhood cancer survivors (CCS). Major risk factors for GHD include radiation therapy, both cranial and total body irradiation, and tumor location. Some newer anti-cancer therapies may impact growth and the GH-IGF-1 axis as well. While untreated childhood-onset GHD adversely impacts adult height in CCS, longstanding GHD can cause or exacerbate multiple metabolic and skeletal health problems. This chapter discusses considerations in the diagnosis and treatment of GHD in CCS and discusses long-term outcomes in survivors of childhood cancer who have GHD.
生长激素缺乏症(GHD)在儿童癌症幸存者(CCS)中很常见。导致 GHD 的主要危险因素包括放疗,包括颅部和全身放疗,以及肿瘤位置。一些新的抗癌疗法也可能会影响生长和 GH-IGF-1 轴。未治疗的儿童期 GHD 会对 CCS 的成年身高产生不利影响,而长期 GHD 会导致或加重多种代谢和骨骼健康问题。本章讨论了 CCS 中 GHD 的诊断和治疗注意事项,并讨论了患有 GHD 的儿童癌症幸存者的长期预后。